ClinicalTrials.gg

Program

Nigella sativa oil

Also written as “NP101”, “NP-101” and “NP101 Sumatriptan Iontophoretic Transdermal Patch”.

Its studies are mostly in Migraine Disorders · Gastro-enteropancreatic neuroendocrine tumor · COVID-19, led by 2 companies.

Furthest: phase 3, since Nov 14, 20087 company-led studies, 1 open or runningNext primary completion: Dec 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Teva Pharmaceutical Industries50 open or runningphase 3since Nov 14, 2008Jul 21, 2008none ahead
Novatek Pharmaceuticals21 open or runningphase 3since Oct 6, 2026Mar 23, 2023Dec 2029phase 3 · NCT07935928

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 21, 2008First studies: 2 phase 1 studies in Migraine DisordersNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00720018, NCT00723983
  2. Nov 14, 2008Phase 3 study in Migraine DisordersTeva Pharmaceutical Industries · NCT00792103 · 198 enrolled · United States
  3. Dec 10, 2008Phase 3 study in Migraine DisordersTeva Pharmaceutical Industries · NCT00806546 · 514 enrolled · United States
  4. Jun 22, 2011Phase 1 study in Compare Bioequivalence Patches Previously Used in the NP101-007 StudyTeva Pharmaceutical Industries · NCT01381796 · 63 enrolled · United States
  5. Mar 23, 2023Novatek Pharmaceuticals’ first study: phase 2 study in COVID-19New to Novatek PharmaceuticalsNovatek Pharmaceuticals · NCT05785390 · 170 enrolled · United States
  6. Oct 6, 2026Phase 3 study in Gastroenteropancreatic Neuroendocrine TumorsPhase 3 reachedNovatek Pharmaceuticals · NCT07935928 · 381 planned

Ahead

  1. Dec 2029Primary completion: phase 3 study in Gastroenteropancreatic Neuroendocrine TumorsNovatek Pharmaceuticals · NCT07935928

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07935928Gastroenteropancreatic Neuroendocrine Tumors3Not yet recruitingNovatek PharmaceuticalsDec 2029381
NCT05785390COVID-19 · United States2TerminatedNovatek PharmaceuticalsMay 9, 2025170
NCT01381796Compare Bioequivalence Patches Previously Used in the NP101-007 Study · United States1CompletedTeva Pharmaceutical IndustriesSep 201063
NCT00806546Migraine Disorders · United States3CompletedTeva Pharmaceutical IndustriesMay 2011514
NCT00792103Migraine Disorders · United States3CompletedTeva Pharmaceutical IndustriesSep 2010198
NCT00723983Migraine Disorders · United States1CompletedTeva Pharmaceutical IndustriesSep 200923
NCT00720018Migraine Disorders · United States1CompletedTeva Pharmaceutical IndustriesJul 20084

How it is read

Names in the registry

  • “NP101”, 3 entries
  • “NP-101”, 2 entries
  • “NP101 Sumatriptan Iontophoretic Transdermal Patch”, 1 entry
  • “NP101 Study Patch”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Nigella sativa oil (Teva Pharmaceutical Industries): development program | ClinicalTrials.gg